about
A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic reviewNorovirusAntiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like ParticlesIntranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccineVirus like particle-based vaccines against emerging infectious disease viruses.Controlling the HIV/AIDS epidemic: current status and global challengesCationic polymer brush-modified cellulose nanocrystals for high-affinity virus binding.Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7Vaccine against norovirus.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccinesEfficient agroinfiltration of plants for high-level transient expression of recombinant proteinsAn intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.Norovirus P particle efficiently elicits innate, humoral and cellular immunityDevelopment of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid.Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceIsolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens.An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesIntranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations.Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function.Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigensNorovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulationPolyvalent complexes for vaccine developmentPlant-derived virus-like particles as vaccinesComparative evaluation of recombinant protein production in different biofactories: the green perspective.Plant-made immunogens and effective delivery strategies.In planta production of plant-derived and non-plant-derived adjuvants.Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.Virus-like particles produced in plants as potential vaccines.Progress towards the prevention and treatment of norovirus infections.Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants.Noroviruses: epidemiology, immunity and prospects for prevention.Nasal and pulmonary vaccine delivery using particulate carriers.Current prospects and future challenges for nasal vaccine delivery.Production of Brazilian human norovirus VLPs and comparison of purification methods.Yeast as an expression system for producing virus-like particles: what factors do we need to consider?
P2860
Q26783083-E5945936-B3C0-41CE-A849-940A0BE0AFF4Q26864280-B96E45AF-2DB9-47FC-998D-D341B1F71642Q28550340-CD8E61AC-1A77-451D-84BF-D99247B55F5FQ28728786-15604F77-B983-47DE-9C40-EE3DA3B1E6CBQ30249025-055C8F2B-10FC-4370-82F2-8E72D6B11236Q30420558-E58E87CA-6E52-4ECA-A4D3-D21B946E0B93Q30846567-2E4DCD5D-1DB4-4485-96F9-07593C226F26Q33569555-85D12B91-6611-4A12-B432-1A9CC75F4C73Q33578075-58A67762-C386-4CC3-8234-4BB8122923ECQ34290717-EB6F2612-BE95-433B-85E6-B041D1415021Q34361669-322AEF57-94F0-4DFB-B293-5B0A060E4D65Q34431983-7F21DF28-DA0B-4EEB-827C-68E7EC42D1DDQ34702360-9C8EA0C1-FEE1-4D57-8FF1-98A62B53FB75Q34778430-D9D6FB96-DCBE-44BF-9932-94518FBF32B7Q34785721-2C47FBD8-1BDB-4882-B267-D95D73B29C01Q34907018-F37A618C-A0E8-42D6-BFD8-BC83E9EE7E6FQ34985473-7F1DE973-7E09-4926-8B53-AB78F4E2229BQ35100779-DA619596-AC13-4C3D-956E-BA844DE5C301Q35112676-82113712-2EFE-4DE4-A555-7FB85562403BQ35656636-C8B301AB-7565-4358-92A9-E059D84AF024Q35754185-D7A6A67D-1629-4E46-902F-CF93E0F00C6CQ35983587-F98AC707-B9F3-4394-A564-AEB955020C00Q36071784-AA869C3A-EC39-4D30-96B9-E766A2FE35F8Q36155501-5A7885A6-AAA0-4EB7-8756-A1BB62A05A86Q36445296-73AFF720-A4F6-464F-81BF-692A5B32A093Q36642590-0C16C1E4-B6F0-455C-BB8B-672FB6250EA1Q36792270-609B5591-C0B7-4062-9C21-F510506C8B31Q36888029-2DE57668-0768-461E-8187-C96132FDF699Q37679720-D88687F0-9501-4E32-89D0-5866E07CA48CQ37776713-98314AC0-6F58-4F47-A05D-7F232A448B65Q37776716-485D837A-7FF6-41D9-953A-40E81136A847Q38081967-F7B12295-6B89-45FD-8C83-4BAFC9BEEEAAQ38081975-4BF8721C-6341-40F0-BBEB-C928D74CE5DCQ38160537-DCF2E10E-D345-4EDC-BABE-874056BAB9A0Q38296952-91B51CF3-6957-4229-BE5D-B2AF9F484CF0Q38322750-923D1BEA-305B-4857-AEB9-C01DEBF6E626Q38465267-729F477A-1558-4118-97FD-852F29438E9FQ38784950-13BF5464-3819-4F3F-8EF8-325CD566575CQ38929391-7022E869-B319-44BF-9B82-56EB574C055FQ39012245-EDEC54F0-4F10-4695-B3EE-DD25E289C0F3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Norwalk virus-like particles as vaccines.
@en
Norwalk virus-like particles as vaccines.
@nl
type
label
Norwalk virus-like particles as vaccines.
@en
Norwalk virus-like particles as vaccines.
@nl
prefLabel
Norwalk virus-like particles as vaccines.
@en
Norwalk virus-like particles as vaccines.
@nl
P2860
P50
P356
P1476
Norwalk virus-like particles as vaccines.
@en
P2860
P304
P356
10.1586/ERV.09.163
P577
2010-03-01T00:00:00Z